垂体后叶素联合肾上腺素应用于心肺复苏治疗效果的meta分析

doi:10.3969/j.issn.1004-583X.2024.03.002

摘要/Abstract

摘要：

目的系统评价垂体后叶素联合肾上腺素应用于心肺复苏治疗的效果。方法计算机检索PubMed、The Cochrane Library、VIP、CNKI、WanFang Date数据库(建库至2022年10月),按照纳入与排除标准选择文献、评价质量并提取资料后,采用RevMan 5.3软件进行meta分析。结果共纳入符合条件的17篇文献,共计1059例患者。Meta分析结果显示:垂体后叶素联合肾上腺素增加自主循环恢复率[RR=2.02, 95%CI(1.74, 2.34),P<0.01],缩短自主循环恢复时间[MD=-8.91, 95%CI(-11.13, -6.69),P<0.01],增加了24 h存活率[RR=2.43, 95%CI(1.86, 3.18),P<0.01]及出院存活率[RR=2.41, 95%CI(1.83, 3.18),P<0.01],降低了终止复苏率[RR=0.39, 95%CI(0.22, 0.68),P=0.001],增加了复苏后6 h尿量[MD=130, 95%CI(113.68, 146.32),P<0.01];但复苏后平均动脉压及心电图ST-T下移两组间差异无统计学意义。结论垂体后叶素联合肾上腺素应用于心肺复苏治疗时,可明显提高复苏成功率,缩短复苏时间,提高患者24 h及出院存活率,增加复苏后6 h尿量,改善器官灌注。

关键词: 心肺复苏术, 垂体后叶素, 肾上腺素, Meta分析

Abstract:

Objective To systematically evaluate the effects of pituitrin combined with epinephrine in treating cardiopulmonary resuscitation (CPR). Methods We retrieved the literatures about pituitrin combined with epinephrine in treating CPR published in PubMed, The Cochrane Library, VIP, China National Knowledge Infrastructure (CNKI) and WanFang Date from inception to October 2022. Literature selection, quality evaluation and data extraction were performed according to inclusion and exclusion criteria, and a meta-analysis was completed by RevMan 5.3. Results Seventeen eligible literatures representing 1059 patients were included. The results of meta-analysis showed that pituitrin combined with epinephrine significantly increased the rate of return of spontaneous circulation (ROSC) (RR=2.02, 95%CI[1.74, 2.34], P<0.01), shorten the time to ROSC (MD=-8.91, 95%CI[-11.13, -6.69], P<0.01), and significantly increased the 24 h survival rate (RR=2.43, 95%CI[1.86, 3.18], P<0.01) and discharge survival rate (RR=2.41, 95%CI[1.83, 3.18], P<0.01), significantly reduced termination-of-resuscitation rate (RR=0.39, 95%CI[0.22, 0.68], P=0.001), significantly increased urine volume at 6 hours after resuscitation (MD=130, 95%CI[113.68, 146.32], P<0.01). However, after resuscitation, there was no significant difference in mean arterial pressure and ST-segment depression on electrocardiography between groups. Conclusion Pituitrin combined with epinephrine on CPR can significantly improve the success rate of resuscitation, shorten the time to resuscitation, improve 24 h and discharge survival rate, increase urine volume at 6 hours after resuscitation, and improve organ perfusion.

Key words: cardiopulmonary resuscitation, pituitrin, epinephrine, Meta-analysis

中图分类号:

R654.1

李冠珠, 杨亚婷, 邓金和, 邵兰, 曾朝坤. 垂体后叶素联合肾上腺素应用于心肺复苏治疗效果的meta分析[J]. 临床荟萃, 2024, 39(3): 208-215.

Li Guanzhu, Yang Yating, Deng Jinhe, Shao Lan, Zeng Chaokun. Effects of pituitrin combined with epinephrine in cardiopulmonary resuscitation: A meta-analysis[J]. Clinical Focus, 2024, 39(3): 208-215.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2024.03.002

https://lchc.magtechjournal.com/CN/Y2024/V39/I3/208

图/表 12

参考文献 38

[1]	Panchal AR, Berg KM, Hirsch KG, et al. 2019 American Heart Association focused update on advanced cardiovascular life support: Use of advanced airways, vasopressors, and extracorporeal cardiopulmonary resuscitation during cardiac arrest: An update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care[J]. Circulation, 2019, 140(24):e881-e894.
[2]	Olasveengen TM, Mancini ME, Perkins GD, et al. Adult basic life support collaborators. adult basic life support: 2020 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations[J]. Circulation, 2020, 142(16_suppl_1):S41-S91.
[3]	Abrams D, MacLaren G, Lorusso R, et al. Extracorporeal cardiopulmonary resuscitation in adults: Evidence and implications[J]. Intensive Care Med, 2022, 48(1):1-15.
[4]	Abella BS. High-quality cardiopulmonary resuscitation: Current and future directions[J]. Curr Opin Crit Care, 2016, 22(3):218-24. doi: 10.1097/MCC.0000000000000296 pmid: 27054627
[5]	Mentzelopoulos SD, Malachias S, Chamos C, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: A randomized clinical trial[J]. JAMA, 2013, 310(3):270-279. doi: 10.1001/jama.2013.7832 pmid: 23860985
[6]	Morgan RW, Kirschen MP, Kilbaugh TJ, et al. Pediatric in-hospital cardiac arrest and cardiopulmonary resuscitation in the united states: A review[J]. JAMA Pediatr. 2021, 175(3):293-302. doi: 10.1001/jamapediatrics.2020.5039 pmid: 33226408
[7]	Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions(version 5.1.0)[EB/OL]. Available at: www.cochrane-handbook.org.
[8]	张楠. 垂体后叶素联合肾上腺素在心肺复苏中的应用效果[J]. 临床医学研究与实践, 2020, 5(19):38-39+42.
[9]	刘喆, 唐鸿祺, 何日德, 等. 联合应用垂体后叶素及肾上腺素在心肺复苏中的临床观察[J]. 泰山医学院学报, 2016, 37(8):848-850.
[10]	刘喆, 姚惠兴. 垂体后叶素在心肺复苏中的应用[J]. 海峡药学, 2015, 27(7):135-136.
[11]	邵宝德. 垂体后叶素和肾上腺素联用在心肺复苏时的临床治疗效果[J]. 北方药学, 2015, 12(12):35.
[12]	刘建凌, 陈军, 林钦汉. 垂体后叶素与肾上腺素联用于心肺复苏的疗效分析[J]. 白求恩医学杂志, 2014, 12(5):463-464.
[13]	吕鋆. 垂体后叶素抢救心跳停搏22例临床观察[J]. 中国社区医师(医学专业), 2013, 15(8):149.
[14]	梁振佳, 钱虹. 垂体后叶素在心肺复苏中的临床应用研究[J]. 吉林医学, 2013, 34(13):2493-2494.
[15]	钟敏华. 垂体后叶素与肾上腺素联用在心肺复苏中疗效观察[J]. 当代医学, 2013, 19(17):6-7.
[16]	蒋勇, 李华丽. 垂体后叶素联合肾上腺素在心肺复苏中的应用[J]. 中国医药科学, 2012, 2(18):28-30.
[17]	浦清. 心肺复苏时联用垂体后叶素和肾上腺素的疗效观察[J]. 人民军医, 2012, 55(1):27-28.
[18]	张丽. 心肺复苏时联用垂体后叶素和肾上腺素的临床观察[J]. 中国当代医药, 2011, 18(10):55+58.
[19]	黄兆章. 垂体后叶素与肾上腺素联用在心肺复苏中的临床观察[J]. 临床急诊杂志, 2010, 11(4):245-246.
[20]	胡运杰. 心肺复苏中肾上腺素和垂体后叶素联合应用的临床观察[J]. 中国当代医药, 2010, 17(29):26-27.
[21]	刘坤, 敖大乔. 心肺复苏时联合应用垂体后叶素及肾上腺素的临床观察[J]. 中国现代医生, 2009, 47(29):42-43.
[22]	张红, 张丽英, 曲雷. 肾上腺素联用垂体后叶素在心肺复苏中的疗效观察[J]. 中国医刊, 2009, 44(9):39-40.
[23]	莫文庆, 邓虹, 赖峰. 垂体后叶素联合肾上腺素在心肺复苏中的疗效观察[J]. 实用医院临床杂志, 2008, 5(2):55-56.
[24]	毕晓锋, 刘国斌, 叶显智. 垂体后叶素在心肺复苏中的应用研究[J]. 海南医学, 2005, 16(11):32-33.
[25]	Newell C, Grier S, Soar J. Airway and ventilation management during cardiopulmonary resuscitation and after successful resuscitation[J]. Crit Care, 2018, 22(1):190.
[26]	Moscarelli A, Iozzo P, Ippolito M, et al. Cardiopulmonary resuscitation in prone position: A scoping review[J]. Am J Emerg Med, 2020, 38(11):2416-2424. doi: 10.1016/j.ajem.2020.08.097 pmid: 33046293
[27]	Brady WJ, Chavez S, Gottlieb M, et al. Clinical update on COVID-19 for the emergency clinician: Cardiac arrest in the out-of-hospital and in-hospital settings[J]. Am J Emerg Med, 2022, 57:114-123. doi: 10.1016/j.ajem.2022.04.031 pmid: 35561501
[28]	Perkins GD, Ji C, Deakin CD, et al. A Randomized trial of epinephrine in out-of-hospital cardiac arrest[J]. N Engl J Med, 2018, 379(8):711-721.
[29]	Soar J. Epinephrine for cardiac arrest: Knowns, unknowns and controversies[J]. Curr Opin Crit Care, 2020, 26(6):590-595. doi: 10.1097/MCC.0000000000000763 pmid: 33109949
[30]	Shao H, Li CS. Epinephrine in out-of-hospital cardiac arrest: Helpful or harmful?[J]. Chin Med J (Engl), 2017, 130(17):2112-2116.
[31]	Sheriff A, Rameshkumar R, Chidambaram M, et al. Epinephrine plus vasopressin vs epinephrine plus placebo in pediatric intensive care unit cardiopulmonary resuscitation: A randomized double blind controlled clinical trial[J]. Indian Pediatr, 2021, 58(7):624-630. pmid: 33612485
[32]	Abdelazeem B, Awad AK, Manasrah N, et al. The Effect of vasopressin and methylprednisolone on return of spontaneous circulation in patients with in-hospital cardiac arrest: A systematic review and meta-analysis of randomized controlled trials[J]. Am J Cardiovasc Drugs, 2022, 22(5):523-533.
[33]	Burgert JM, Johnson AD, Garcia-Blanco J, et al. The resuscitative and pharmacokinetic effects of humeral intraosseous vasopressin in a swine model of ventricular fibrillation[J]. Prehosp Disaster Med, 2017, 32(3):305-310. doi: 10.1017/S1049023X17000140 pmid: 28270248
[34]	Gough CJR, Nolan JP. The role of adrenaline in cardiopulmonary resuscitation[J]. Crit Care, 2018, 22(1):139.
[35]	Sankaran D, Chandrasekharan PK, Gugino SF, et al. Randomised trial of epinephrine dose and flush volume in term newborn lambs[J]. Arch Dis Child Fetal Neonatal Ed, 2021, 106(6):578-583.
[36]	Zhang Z, Shi HW, Sun JH, et al. Use of hypophysin in hypotensive patients with low systemic vascular resistance following cardiopulmonary bypass[J]. Int J Clin Pharmacol Ther, 2013, 51(8):615-619.
[37]	Sims CA, Holena D, Kim P, et al. Effect of low-dose supplementation of arginine vasopressin on need for blood product transfusions in patients with trauma and hemorrhagic shock: A randomized clinical trial[J]. JAMA Surg, 2019, 154(11):994-1003. doi: 10.1001/jamasurg.2019.2884 pmid: 31461138
[38]	Johnson D, Giles K, Acuna A, et al. Effects of tibial intraosseous and IV administration of vasopressin on kinetics and survivability in cardiac arrest[J]. Am J Emerg Med, 2016, 34(3):429-432. doi: 10.1016/j.ajem.2015.11.027 pmid: 26778642

纳入研究	样本量 (P/E)	年龄(岁) (P/E)	患者类型	干预措施(P/E)	结局指标
张楠2020^[8]	23/23	65.7±5.6 65.4±5.3	呼吸心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	④
刘喆2016 ^[9]	36/36	56.1±2.3 55.7±2.1	心肺复苏患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④⑥⑦⑧
刘喆2015^[10]	19/19	31.32±2.71	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③
邵宝德2015^[11]	50/50	48.7±13.4 50.2±10.3	呼吸心跳骤停患	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④
刘建凌2014^[12]	25/25	64.27±5.36 64.65±5.39	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④
吕鋆2013^[13]	22/18	60.2±19.4	心跳骤停患者	垂体后叶素24 U+肾上腺素1 mg/肾上腺素1 mg	①④
梁振佳2013^[14]	31/29	56±17	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②⑤
钟敏华2013^[15]	31/30	60.2±19.6	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④⑤
蒋勇2012^[16]	26/19	52.3±4.5	呼吸心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④⑥⑦⑧
浦清2012^[17]	45/45	50.5	呼吸心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③⑥
张丽2011^[18]	30/29	61.4±21.5	心跳骤停患者	垂体后叶素20 U+肾上腺素1 mg/肾上腺素1 mg	①②③④
黄兆章2010^[19]	26/23	58.7±19.6	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①④
胡运杰2010^[20]	52/51	63.1	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①④⑤
刘坤2009^[21]	32/30	/	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④
张红2009^[22]	26/30	64	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③
莫文庆2008^[23]	30/28	62.4±21.8	心跳骤停患者	垂体后叶素20 U+肾上腺素1 mg/肾上腺素1 mg	①②③④
毕晓峰2005^[24]	37/31	62.4±20.2	心跳骤停患者	垂体后叶素20 U+肾上腺素1 mg/肾上腺素1 mg	①②

纳入研究	样本量 (P/E)	年龄(岁) (P/E)	患者类型	干预措施(P/E)	结局指标
张楠2020^[8]	23/23	65.7±5.6 65.4±5.3	呼吸心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	④
刘喆2016 ^[9]	36/36	56.1±2.3 55.7±2.1	心肺复苏患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④⑥⑦⑧
刘喆2015^[10]	19/19	31.32±2.71	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③
邵宝德2015^[11]	50/50	48.7±13.4 50.2±10.3	呼吸心跳骤停患	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④
刘建凌2014^[12]	25/25	64.27±5.36 64.65±5.39	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④
吕鋆2013^[13]	22/18	60.2±19.4	心跳骤停患者	垂体后叶素24 U+肾上腺素1 mg/肾上腺素1 mg	①④
梁振佳2013^[14]	31/29	56±17	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②⑤
钟敏华2013^[15]	31/30	60.2±19.6	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④⑤
蒋勇2012^[16]	26/19	52.3±4.5	呼吸心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④⑥⑦⑧
浦清2012^[17]	45/45	50.5	呼吸心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③⑥
张丽2011^[18]	30/29	61.4±21.5	心跳骤停患者	垂体后叶素20 U+肾上腺素1 mg/肾上腺素1 mg	①②③④
黄兆章2010^[19]	26/23	58.7±19.6	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①④
胡运杰2010^[20]	52/51	63.1	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①④⑤
刘坤2009^[21]	32/30	/	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③④
张红2009^[22]	26/30	64	心跳骤停患者	垂体后叶素40 U+肾上腺素1 mg/肾上腺素1 mg	①②③
莫文庆2008^[23]	30/28	62.4±21.8	心跳骤停患者	垂体后叶素20 U+肾上腺素1 mg/肾上腺素1 mg	①②③④
毕晓峰2005^[24]	37/31	62.4±20.2	心跳骤停患者	垂体后叶素20 U+肾上腺素1 mg/肾上腺素1 mg	①②